Sabrina Serani

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Preliminary data highlights gedatolisib's potential in treating mCRPC and HER2+ mBC, showcasing promising efficacy and a favorable safety profile.

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after chemotherapy.

A new trial optimizes rhenium Re 186 obisbemeda dosing for treating leptomeningeal metastases, aiming to enhance safety and efficacy in CNS cancer therapy.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer tumor resections in glioma surgeries.

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.

Elraglusib shows promise in enhancing survival rates for metastatic pancreatic cancer, particularly in high-risk patients with liver metastases.

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, and CRC through targeted therapies and combinations.

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with platinum-resistant ovarian cancer.

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large B-cell lymphoma, offering a chemotherapy-free option.

FDA prioritizes review of revumenib for relapsed NPM1-mutant AML, highlighting a breakthrough in targeted cancer therapies.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options.

Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.

This week in oncology highlights: FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

A novel combination therapy shows high response rates in relapsed DLBCL, enhancing eligibility for autologous stem cell transplantation.

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

Lisocabtagene maraleucel led to promising responses in relapsed/refractory marginal zone lymphoma, offering a new option with manageable safety.

Catch up on the week's latest oncology news, from clinical trial updates to FDA approvals.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.